PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
121.05%
Net income growth above 20% – Outstanding. Warren Buffett would verify whether this rise is driven by core operations or one-time items.
473.10%
D&A above 15% yoy – Large jump. Philip Fisher would demand significant returns to validate the extra depreciation load.
20.60%
Deferred taxes 20-30% yoy – Larger liability accumulation. Howard Marks would consider if rising tax obligations hamper future free cash flow.
-20.60%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
534.15%
Working capital above 30% yoy – Very high. Philip Fisher would demand clarity on whether the buildup is strategic or signals inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.02%
AP above 30% yoy – High. Philip Fisher would suspect possible cash strain or very aggressive use of supplier credit.
107.35%
Above 30% yoy – Major jump. Philip Fisher would demand details on these miscellaneous lines to ensure transparency.
-145.76%
A negative yoy shift in other non-cash items can lower reported volatility. Benjamin Graham would confirm it is not concealing real operational costs or artificially inflating net income.
-3.22%
Negative yoy CFO growth indicates a decline in core cash generation. Benjamin Graham would treat it as a serious warning unless cyclical factors explain it.
-7359.68%
A negative yoy CapEx shift boosts near-term FCF if capacity is adequate. Benjamin Graham would see it as beneficial unless future growth is sacrificed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Above 20% yoy – Large jump. Philip Fisher would demand clarity on whether these “other” items overshadow core expansions.
-7359.68%
A negative yoy shift suggests smaller outflows or net inflows if disposals exceed invests. Benjamin Graham would see a short-term FCF benefit unless growth is compromised.
37.62%
Debt repayment growth above 20% yoy – Strong deleveraging. Warren Buffett would see improved balance sheet health unless expansions are starved.
299.00%
Issuance above 15% yoy – Significant equity raise. Philip Fisher would require a very compelling reason to risk heavy shareholder dilution.
No Data
No Data available this quarter, please select a different quarter.